TLE family member 1, transcriptional corepressorGenealiases: ESG · ESG1 · GRG1 · TLE-1
Q-omics provides the consensus-scored TLE1 profile across patient tissues and cancer cell-line models. TLE1 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in LUAD. Among the 18 cancer types available for tumor–normal comparison, TLE1 is differentially expressed in 12, with the highest sampling consensus in THCA. Additionally, TLE1 RNA expression shows 19,042 significant gene co-expression associations, with the highest sampling consensus in ACC. Together, these results highlight LUAD, THCA, and ACC as cancer lineages where TLE1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TLE1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TLE1 survival associations across molecular data types. TLE1 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (6) and mass-spec protein abundance (7). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TLE1 RNA expression–survival associations across cancer types. High TLE1 expression shows unfavorable associations in LUAD, ACC, BRCA, MESO and THCA, but favorable associations in SCLC. The LUAD Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify LUAD as the clearest survival context for TLE1 RNA expression.
This table summarizes TLE1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 12, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and PDAC for protein.
This table ranks reproducible tumor–normal expression differences for TLE1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TLE1 shows lower tumor expression in THCA and BRCA and higher tumor expression in HNSC, LIHC, KIRP and LUSC. The THCA box plot shows higher TLE1 RNA expression in normal versus tumor tissue (log2 FC = −1.858, t-test p < 0.001).
This table shows molecular features associated with TLE1 in patient tissues and cancer cell lines. In patient samples, TLE1 shows the broadest associations at the RNA and protein expression levels, with ACC recurring as the lineage with the largest associated feature set. In cancer cell lines, TLE1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in STOMACH and BLOOD_Leukemia.
